Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director comp.
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
Docs: " "
08/17/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: " "
08/14/2023 8-K Quarterly results
Docs: "Reviva Reports Second Quarter 2023 Financial Results and Recent Business Highlights"
07/24/2023 8-K Quarterly results
04/27/2023 8-K Quarterly results
03/30/2023 8-K Quarterly results
01/04/2023 8-K Quarterly results
11/14/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
09/07/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "PRE-FUNDED COMMON STOCK PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC. Warrant Shares: _______ Issue Date: September 8, 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation , up to ______ shares of common stock, par value $0.0001 per share . The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms use...",
"COMMON STOCK PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC. Warrant Shares: _______ Initial Exercise Date: September 8, 2022 Issue Date: September 8, 2022 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after September 8, 2022 and on or prior to 5:00 p.m. on September 8, 2027 but not thereafter, to subscribe for and purchase from Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation , up to ______ shares of common stock, par value $0.0001 per share . The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Defi...",
" ",
"SECURITIES PURCHASE AGREEMENT",
"SECURITIES PURCHASE AGREEMENT",
" ",
" "
08/15/2022 8-K Quarterly results
07/28/2022 8-K Quarterly results
07/27/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
03/15/2022 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2021 Financial Results and Recent Business Highlights"
02/01/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: " "
01/26/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
12/10/2021 8-K Quarterly results
11/15/2021 8-K Quarterly results
Docs: "Reviva Pharmaceuticals Holdings, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Highlights"
09/20/2021 8-K Quarterly results
08/16/2021 8-K Quarterly results
06/16/2021 8-K Quarterly results
05/10/2021 8-K Results of Operations and Financial Condition
05/07/2021 8-K Results of Operations and Financial Condition, Non-Reliance on Previously Issued Financial Statements or a Related Audit Repo...
04/15/2021 8-K Quarterly results
03/22/2021 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Reviva Pharmaceuticals Holdings, Inc. Reports 2020 Financial Results and Provides Corporate Update"
03/04/2021 8-K Quarterly results
12/18/2020 8-K Director compensation was amended/approved
Docs: "Certificate of Corporate Domestication",
"Amended and Restated Certificate of Incorporation",
"Form of Assumed Warrant",
"Employment Agreement, by and between the Company and Dr. Bhat",
"Offer of Employment, by and between Marc Cantillon, MD and Reviva Pharmaceuticals, Inc",
"Letter Agreement, by and between Marc Cantillon, MD and Reviva Pharmaceuticals, Inc",
"Letter Agreement, by and between Marc Cantillon, MD and Reviva Pharmaceuticals, Inc",
"Form of Indemnification Agreement",
"Saxena Indemnification Agreement",
"Form of Non-Redemption Agreement, by and among the Company, Tenzing LLC and the shareholder party thereto"
12/14/2020 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Certificate of Incorporation of Reviva Pharmaceuticals Holdings, Inc",
"Bylaws of Reviva Pharmaceuticals Holdings, Inc",
"Press Release"
12/09/2020 8-K Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders
11/19/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Press Release"
11/13/2020 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial ...
Docs: "Promissory Note, issued by Tenzing Acquisition Corp. to Tenzing LLC"
10/27/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Form of Waiver Letter, by Tenzing Acquisition Corp. and Reviva Pharmaceuticals, Inc. for the benefit of the Investor named therein"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy